

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary Fiscal 2014 Interim

(January 1, 2014 - June 30, 2014)

- This document was made as a supplement to the Kessan Tanshin (financial report), disclosed at the Tokyo Stock Exchange on July 30, for the interim of Fiscal 2014, the six-month period from January 1, 2014 to June 30, 2014.
- This document contains forward-looking statements based on a member of assumptions and beliefs held by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.
- Figures presented in this document have been rounded down to the nearest whole number.

Index	Page
I. Consolidated Financial Results	
1. Trends in consolidated income	1
2. Trends in results by segment	2
3. Other trends	3
II. Consolidated Balance Sheets	4
III. Consolidated Cash Flows	5
IV. Consolidated Subsidiaries and Affiliates	6
V. Kyowa Hakko Kirin Sales of Main Products	7
VI. Segment Information and Main Subsidiaries Operating Profit or Loss	
1. Pharmaceuticals segment	9
2. Bio-Chemicals segment	10
VII. R&D Pipeline	11

The average exchange rate for each period was as follows

Unit: yen

	2013 results				2014 results				2014 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
US \$	89	94	95	96	103	103			102
EURO	118	123	125	127	141	141			141
GBP	141	145	147	150	171	171			171

Contact
 Kyowa Hakko Kirin Co., Ltd.
 Corporate Communications Department
 Tel 81 3 3282 0009

I. Consolidated Financial Results

1. Trends in consolidated income

Accumulative

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY2014 Forecast		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	86.6	169.7	252.1	340.6	86.0	99%	161.8	(7.8)	95%	-	-	-	-	337.0	99%
Gross Profit	52.3	105.1	157.2	212.7	51.2	98%	98.2	(6.9)	93%	-	-	-	-	-	-
Selling, general and administrative expenses	37.8	77.9	115.8	160.9	38.8	103%	79.8	1.8	102%	-	-	-	-	-	-
Operating income (prior to amortization of goodwill)	16.7	31.8	48.3	61.0	14.7	88%	23.0	(8.7)	72%	-	-	-	-	54.2	89%
Operating income	14.4	27.1	41.4	51.7	12.4	86%	18.4	(8.7)	68%	-	-	-	-	45.0	87%
Non-operating income	1.0	2.4	2.9	4.4	1.0	96%	1.6	(0.7)	67%	-	-	-	-	-	-
Non-operating expenses	0.6	3.0	5.1	6.7	1.3	207%	3.1	0.0	103%	-	-	-	-	-	-
Ordinary income	14.8	26.5	39.2	49.5	12.0	81%	16.8	(9.6)	64%	-	-	-	-	37.0	75%
Extraordinary income	3.8	4.4	4.9	4.9	0.3	8%	0.3	(4.1)	7%	-	-	-	-	-	-
Extraordinary loss	-	0.1	3.6	4.7	-	-	0.4	0.2	346%	-	-	-	-	-	-
Income before income taxes and minority interests	18.6	30.8	40.4	49.7	12.3	66%	16.7	(14.1)	54%	-	-	-	-	35.5	71%
Income taxes	8.1	13.1	17.1	19.6	6.0	74%	7.5	(5.5)	58%	-	-	-	-	-	-
Minority interests in income	0.0	0.0	0.0	0.0	-	-	-	(0.0)	-	-	-	-	-	-	-
Net income	10.4	17.6	23.3	30.0	6.3	60%	9.1	(8.4)	52%	-	-	-	-	20.0	66%
Comprehensive income	16.8	28.9	36.7	51.8	3.8	23%	6.6	(22.2)	23%	-	-	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	23.39	40.75	55.29	71.85	15.80	68%	25.24	(15.51)	62%	-	-	-	-	53.45	74%

* "Prior to amortization of goodwill" refers to profits prior to the deduction of amortization of the goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

(Note: This adjustment does not include goodwill amortization in respect of the acquisition of ProStrakan.)

* Changes have been made to forecasts for the fiscal year ending December 31, 2014 announced on January 31, 2014 listed in this document. In addition, the estimated effect of the July 11, 2014 announcement—"ProStrakan enters into agreement to buy Archimedes"—has not been factored into forecasts.

Quarterly

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	%	Apr - Jun	Change Amount	%	Jul - Sep	%	Oct - Dec	%
Net sales	86.6	83.0	82.3	88.5	86.0	99%	75.8	(7.2)	91%	-	-	-	-
Gross Profit	52.3	52.7	52.1	55.4	51.2	98%	46.9	(5.8)	89%	-	-	-	-
Selling, general and administrative expenses	37.8	40.0	37.8	45.1	38.8	103%	40.9	0.8	102%	-	-	-	-
Operating income (Prior to amortization of goodwill)	16.7	15.0	16.5	12.6	14.7	88%	8.2	(6.7)	55%	-	-	-	-
Operating income	14.4	12.7	14.2	10.3	12.4	86%	5.9	(6.7)	47%	-	-	-	-
Non-operating income	1.0	1.3	0.5	1.4	1.0	96%	0.5	(0.7)	44%	-	-	-	-
Non-operating expenses	0.6	2.3	2.1	1.5	1.3	207%	1.7	(0.6)	74%	-	-	-	-
Ordinary income	14.8	11.6	12.6	10.2	12.0	81%	4.8	(6.8)	41%	-	-	-	-
Extraordinary income	3.8	0.6	0.5	0.0	0.3	8%	-	(0.6)	-	-	-	-	-
Extraordinary loss	-	0.1	3.5	1.0	-	-	0.4	0.2	346%	-	-	-	-
Income before income taxes and minority interests	18.6	12.2	9.6	9.2	12.3	66%	4.3	(7.8)	36%	-	-	-	-
Income taxes	8.1	4.9	3.9	2.4	6.0	74%	1.5	(3.4)	31%	-	-	-	-
Minority interests in income	0.0	0.0	0.0	0.0	-	-	-	(0.0)	-	-	-	-	-
Net income	10.4	7.1	5.6	6.7	6.3	60%	2.8	(4.3)	40%	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	23.39	17.36	14.54	16.57	15.80	68%	9.44	(7.92)	54%	-	-	-	-

I. Consolidated Financial Results

2. Trends in results by segment

(1) Reported segment

Accumulative

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY2014 Forecast		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change Amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	86.6	169.7	252.1	340.6	86.0	99%	161.8	(7.8)	95%	-	-	-	-	337.0	99%
Pharmaceuticals	67.4	129.9	192.7	261.0	63.1	94%	119.5	(10.4)	92%	-	-	-	-	252.0	97%
Bio-Chemicals	19.9	41.2	61.5	82.9	23.5	118%	44.0	2.8	107%	-	-	-	-	88.0	106%
Total	87.4	171.1	254.3	343.9	86.7	99%	163.5	(7.5)	96%	-	-	-	-	340.0	99%
Eliminations	(0.7)	(1.4)	(2.2)	(3.3)	(0.6)	-	(1.6)	(0.2)	-	-	-	-	-	(3.0)	-
Operating income	14.4	27.1	41.4	51.7	12.4	86%	18.4	(8.7)	68%	-	-	-	-	45.0	87%
Before goodwill amortization	16.7	31.8	48.3	61.0	14.7	88%	23.0	(8.7)	72%	-	-	-	-	54.2	89%
Pharmaceuticals	13.0	24.1	36.9	46.1	9.4	72%	14.1	(9.9)	59%	-	-	-	-	37.0	80%
Bio-Chemicals	15.2	28.4	43.4	54.7	11.5	76%	18.4	(9.9)	65%	-	-	-	-	45.6	83%
Total	1.4	3.1	4.5	5.6	3.0	206%	4.2	1.1	136%	-	-	-	-	8.0	141%
Eliminations	1.6	3.4	4.9	6.2	3.2	196%	4.5	1.1	133%	-	-	-	-	8.6	137%
Total	14.5	27.2	41.4	51.8	12.4	86%	18.4	(8.8)	68%	-	-	-	-	45.0	87%
Eliminations	16.8	31.8	48.4	61.0	14.8	88%	23.0	(8.8)	72%	-	-	-	-	54.2	89%
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-	0.0	0.0	-	-	-	-	-	-	-

Quarterly

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	%	Apr - Jun	Change Amount	%	Jul - Sep	%	Oct - Dec	%
Net sales	86.6	83.0	82.3	88.5	86.0	99%	75.8	(7.2)	91%	-	-	-	-
Pharmaceuticals	67.4	62.5	62.8	68.2	63.1	94%	56.3	(6.1)	90%	-	-	-	-
Bio-Chemicals	19.9	21.2	20.3	21.3	23.5	118%	20.4	(0.7)	96%	-	-	-	-
Total	87.4	83.7	83.2	89.5	86.7	99%	76.8	(6.9)	92%	-	-	-	-
Eliminations	(0.7)	(0.6)	(0.8)	(1.0)	(0.6)	-	(1.0)	(0.3)	-	-	-	-	-
Operating income	14.4	12.7	14.2	10.3	12.4	86%	5.9	(6.7)	47%	-	-	-	-
Before goodwill amortization	16.7	15.0	16.5	12.6	14.7	88%	8.2	(6.7)	55%	-	-	-	-
Pharmaceuticals	13.0	11.0	12.8	9.1	9.4	72%	4.7	(6.3)	43%	-	-	-	-
Bio-Chemicals	15.2	13.2	14.9	11.3	11.5	76%	6.8	(6.3)	52%	-	-	-	-
Total	1.4	1.6	1.4	1.1	3.0	206%	1.1	(0.4)	72%	-	-	-	-
Eliminations	1.6	1.7	1.5	1.3	3.2	196%	1.3	(0.4)	75%	-	-	-	-
Total	14.5	12.6	14.2	10.3	12.4	86%	5.9	(6.7)	47%	-	-	-	-
Eliminations	16.8	15.0	16.5	12.6	14.8	88%	8.2	(6.7)	55%	-	-	-	-
Eliminations	(0.0)	0.0	(0.0)	0.0	(0.0)	-	0.0	0.0	216%	-	-	-	-

(2) Regional sales

Billions of yen, rounded down

	FY 2013 results						FY 2014 results									
	Jan - Mar	% of consolidated sales	Jan - Jun	% of consolidated sales	Jan - Sep	% of consolidated sales	Jan - Dec	% of consolidated sales	Jan - Mar	% of consolidated sales	Jan - Jun	% of consolidated sales	Jan - Sep	% of consolidated sales	Jan - Dec	% of consolidated sales
Japan sales	66.1	76.3%	127.7	75.3%	188.9	75.0%	254.0	74.6%	61.8	71.9%	115.7	71.5%	-	-	-	-
Overseas sales	20.5	23.7%	41.9	24.7%	63.1	25.0%	86.5	25.4%	24.2	28.1%	46.1	28.5%	-	-	-	-
America	5.2	6.0%	11.1	6.6%	16.3	6.5%	23.9	7.0%	5.5	6.4%	11.4	7.1%	-	-	-	-
Europe	9.4	10.9%	18.5	10.9%	28.1	11.1%	37.2	10.9%	11.0	12.8%	21.3	13.2%	-	-	-	-
Asia	5.7	6.6%	11.8	7.0%	18.0	7.1%	24.4	7.2%	7.3	8.5%	12.8	8.0%	-	-	-	-
Other regions	0.1	0.2%	0.3	0.2%	0.6	0.3%	0.9	0.3%	0.2	0.3%	0.4	0.3%	-	-	-	-
Total consolidated net sales	86.6	100%	169.7	100%	252.1	100%	340.6	100%	86.0	100%	161.8	100%	-	-	-	-

* Sales classified by region or country based on location of customer.

I. Consolidated Financial Results

3. Other trends

(1) R&D Expenses

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
R&D expenses	10.6	21.0	30.7	43.6	10.3	21.9	-	-	45.0
<i>R&D to net sales ratio</i>	12.3%	12.4%	12.2%	12.8%	12.0%	13.5%	-	-	13.4%
Pharmaceuticals	9.8	19.3	28.3	40.4	9.5	20.2	-	-	41.5
<i>R&D to net sales ratio</i>	14.7%	14.9%	14.7%	15.5%	15.2%	16.9%	-	-	16.5%
Bio-Chemicals	0.7	1.6	2.4	3.2	0.7	1.7	-	-	3.5

(2) Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Capital expenditure	5.3	9.6	16.6	24.8	5.3	12.1	-	-	30.0
Pharmaceuticals	1.8	4.4	7.4	12.6	2.8	6.5	-	-	18.5
Bio-Chemicals	3.5	5.1	9.2	12.2	2.4	5.5	-	-	11.5

(3) Depreciation and Amortization Expenses (Tangible and intangible fixed assets)

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Depreciation and amortization expenses	4.8	9.9	15.5	21.5	5.2	10.8	-	-	22.9
<i>Amortization of intangible fixed assets</i>	1.5	3.1	4.9	6.9	1.9	3.9	-	-	8.0
Pharmaceuticals	3.3	6.8	10.7	14.9	3.6	7.6	-	-	16.2
<i>Amortization of intangible fixed assets</i>	1.5	3.1	4.9	6.9	1.9	3.8	-	-	8.0
Bio-Chemicals	1.5	3.0	4.7	6.6	1.5	3.2	-	-	6.7

*Depreciation expenses for intangible fixed assets do not include goodwill amortization expenses

(4) Goodwill Amortization Expenses

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Amortization expenses	2.8	5.7	8.6	11.5	3.0	6.0	-	-	12.1
<i>Reverse acquisition goodwill amortization expenses</i>	2.3	4.6	6.9	9.2	2.3	4.6	-	-	9.2
Pharmaceuticals	2.7	5.4	8.1	10.9	2.8	5.6	-	-	11.2
<i>Reverse acquisition goodwill amortization expenses</i>	2.1	4.3	6.4	8.6	2.1	4.3	-	-	8.6
Bio-Chemicals	0.1	0.3	0.4	0.6	0.2	0.4	-	-	0.9
<i>Reverse acquisition goodwill amortization expenses</i>	0.1	0.3	0.4	0.6	0.1	0.3	-	-	0.6

**"Reverse acquisition goodwill amortization expenses" refers to amortization of goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

II. Consolidated Balance Sheets

Billions of yen, rounded down

	2012	2013				2014				
	Dec 31	Mar 31	June 30	Sep 30	Dec 31	Mar 31	June 30	Change previous year end	Sep 30	Dec 31
Assets	679.3	694.1	691.4	691.2	719.2	689.9	683.1	(36.1)	-	-
Current assets	303.9	310.0	306.5	305.5	329.3	300.8	296.0	(33.2)	-	-
Cash and deposits	21.5	23.2	24.8	21.4	20.1	17.2	15.5	(4.6)	-	-
Notes and accounts receivable-trade	101.5	103.5	98.5	92.0	98.6	102.9	93.4	(5.1)	-	-
Inventories	63.4	68.7	70.9	72.8	75.7	78.9	79.9	4.2	-	-
Deferred tax assets	10.3	10.6	10.6	10.7	10.4	10.2	10.3	(0.0)	-	-
Short-term loans receivable	98.1	97.3	94.1	101.1	113.1	85.1	89.6	(23.4)	-	-
Other	8.8	6.5	7.3	7.4	11.2	6.3	7.1	(4.1)	-	-
Noncurrent assets	375.3	384.0	384.8	385.7	389.9	389.0	387.0	(2.8)	-	-
Property, plant and equipment	126.8	129.6	130.2	133.4	137.9	139.4	142.2	4.3	-	-
Buildings and structures	40.7	40.5	40.4	40.4	42.2	41.3	42.0	(0.1)	-	-
Machinery, equipment and vehicles	19.3	19.0	19.8	19.5	21.0	21.5	21.6	0.5	-	-
Land	53.3	55.2	54.8	54.6	54.6	54.5	54.4	(0.1)	-	-
Other	13.3	14.7	15.1	18.7	20.0	21.9	24.0	4.0	-	-
Intangible assets	207.5	214.5	212.9	210.9	212.0	207.6	203.0	(9.0)	-	-
Goodwill	168.8	166.7	165.2	163.7	163.7	161.6	158.8	(4.8)	-	-
Marketing rights	36.2	45.5	45.5	45.2	46.5	44.3	42.8	(3.6)	-	-
Other	2.4	2.2	2.1	1.9	1.8	1.6	1.4	(0.4)	-	-
Investments and other assets	40.9	39.9	41.7	41.3	39.9	41.9	41.7	1.8	-	-
Investment securities	23.6	22.9	24.7	24.0	24.6	23.4	23.1	(1.4)	-	-
Deferred tax assets	7.7	6.7	6.3	6.4	3.8	3.9	3.9	0.0	-	-
Other	9.5	10.2	10.6	10.9	11.4	14.5	14.6	3.2	-	-
Liabilities	123.4	126.9	112.0	110.9	123.8	98.4	88.8	(35.0)	-	-
Current liabilities	85.7	89.9	77.3	73.1	85.0	76.7	67.2	(17.8)	-	-
Notes and accounts payable-trade	26.3	30.5	23.4	17.9	22.5	26.0	17.5	(5.0)	-	-
Short-term loans payable	5.6	5.7	5.8	5.5	6.2	4.8	5.7	(0.4)	-	-
Accounts payable-other	29.0	32.5	26.5	26.4	36.5	27.3	28.3	(8.1)	-	-
Income taxes payable	15.7	8.0	12.8	11.2	10.4	5.4	7.2	(3.2)	-	-
Provision	1.2	5.1	1.2	5.2	1.8	5.5	1.5	(0.2)	-	-
Other	7.7	7.8	7.4	6.7	7.4	7.5	6.6	(0.7)	-	-
Noncurrent liabilities	37.6	36.9	34.6	37.7	38.7	21.7	21.6	(17.1)	-	-
Deferred tax liabilities	11.2	11.3	11.5	11.4	11.8	11.3	11.3	(0.4)	-	-
Provision	19.9	19.5	19.6	22.9	22.9	6.4	6.3	(16.6)	-	-
Other	6.4	6.0	3.4	3.4	3.9	3.9	3.9	(0.0)	-	-
Net assets	555.8	567.2	579.3	580.3	595.4	591.4	594.3	(1.0)	-	-
Shareholders' equity	560.6	565.6	572.8	571.6	578.3	577.8	580.6	2.3	-	-
Capital stock	26.7	26.7	26.7	26.7	26.7	26.7	26.7	-	-	-
Capital surplus	512.3	512.3	512.3	512.3	512.3	512.3	512.3	(0.0)	-	-
Retained earnings	48.1	53.1	60.3	59.1	65.8	65.3	68.2	2.3	-	-
Treasury stock	(26.5)	(26.5)	(26.5)	(26.5)	(26.6)	(26.5)	(26.6)	0.0	-	-
Accumulated other comprehensive income	(5.7)	0.4	5.2	7.4	15.6	13.3	13.3	(2.2)	-	-
Valuation difference on available-for-sale securities	(2.2)	(0.0)	0.9	1.0	1.4	1.2	1.4	0.0	-	-
Foreign currency translation adjustment	(3.5)	0.4	4.2	6.3	14.2	12.1	11.8	(2.3)	-	-
Subscription rights to shares	0.2	0.2	0.2	0.2	0.3	0.2	0.3	(0.0)	-	-
Minority interests	0.8	0.9	1.0	1.0	1.1	-	-	(1.1)	-	-
Total liabilities and net assets	679.3	694.1	691.4	691.2	719.2	689.9	683.1	(36.1)	-	-

III. Consolidated cash flows

Billions of yen, rounded down

	2012	2013		2014		Breakdown
	Jan-Dec	Jan-Jun	Jan-Dec	Jan-Jun	Change	
Cash flows from operating activities	59.1	20.6	56.8	(0.5)	(21.2)	
Net income before taxes and minority interests	45.0	30.8	49.7	16.7	(14.1)	Net income 9.1 Tax expense 7.5
Accumulated depreciation expense	20.9	9.9	21.5	10.8	0.8	
Amortization of goodwill	12.0	5.7	11.5	6.0	0.3	
Other non-capital gain or loss	0.7	(0.8)	(1.2)	(0.8)	0.0	
Gain (loss) relating to investing activities	5.4	(2.2)	(0.2)	1.4	3.7	
Increase (decrease) in working capital	(5.8)	(5.5)	(5.6)	(4.6)	0.8	Changes in notes and accounts receivables-trade 4.7 Changes in inventories (4.9) Changes in notes and accounts payable-trade (4.4)
Income taxes paid	(15.9)	(16.5)	(23.1)	(11.6)	4.9	
Other	(3.1)	(0.6)	4.3	(18.5)	(17.9)	Contribution to retirement benefit trust (19.0)
Cash flows from investing activities	(98.7)	(34.2)	(77.1)	1.6	35.8	
Purchase of property, plant and equipment	(17.5)	(10.7)	(21.5)	(16.3)	(5.5)	
Proceeds from sales of property, plant and equipment	0.4	1.6	1.7	0.1	(1.5)	
Purchase of intangible assets	(9.3)	(12.7)	(13.1)	(1.9)	10.7	
Purchase of investment securities	(6.4)	(1.9)	(3.8)	(1.1)	0.8	
Proceeds from sales of investment securities	2.4	3.7	3.9	0.0	(3.7)	
Proceeds from sales of stocks of subsidiaries and affiliates	0.0	3.2	3.7	1.0	(2.2)	
Purchase of investments in subsidiaries resulting in change in scope of consolidation	(0.1)	-	-	-	-	
Net increase (decrease) in short-term loans receivable	(66.9)	(15.9)	(43.0)	20.4	36.4	Short-term loan receivable (exceeding 3 months) to Kirin Holdings
Other	(1.1)	(1.3)	(5.0)	(0.5)	0.8	
Cash flows from financing activities	(19.1)	(5.3)	(12.5)	(7.8)	(2.5)	
Net increase (decrease) of loans payable	(0.4)	0.3	0.0	(0.8)	(1.2)	
Purchase of treasury stock	(7.5)	(0.0)	(0.1)	(0.0)	0.0	
Cash dividends paid	(11.0)	(5.4)	(12.3)	(6.8)	(1.3)	
Other	(0.1)	(0.0)	(0.1)	(0.0)	(0.0)	
Translation differences relating to cash and cash equivalents	1.6	1.0	1.7	(1.0)	(2.0)	
Increase (decrease) in cash and cash equivalents	(57.2)	(17.8)	(31.0)	(7.8)	10.0	
Cash and cash equivalents at beginning of year	107.5	50.3	50.3	19.2	(31.0)	
Cash and cash equivalents at end of year*	50.3	32.5	19.2	11.4	(21.0)	

*Cash and cash deposits in the consolidated balance sheet, cash and cash equivalents at end of year in consolidated cash flows, and cash reserves at end of year

Cash and deposit accounts (consolidated balance sheet)	21.5	24.8	20.1	15.5	(9.3)
Fixed deposits in excess of three months	(2.4)	(3.5)	(3.4)	(3.3)	0.1
Short-term loans receivable to the parent company not exceeding three months ¹	31.1	11.1	3.1	0.1	(11.0)
Current loans payable as negative cash equivalents (short-term loans payable)	-	-	(0.6)	(0.9)	(0.9)
Cash and cash equivalents at end of year (consolidated cash flows)	50.3	32.5	19.2	11.4	(21.0)
Fixed deposits in excess of three months	2.4	3.5	3.4	3.3	(0.1)
Short-term loans receivable to the parent company in excess of three months ¹	67.0	83.0	110.0	89.5	6.5
Cash reserves at end of year	119.7	119.0	132.6	104.2	(14.7)

¹ Based on cash management system (CMS) provided by our parent, Kirin Holdings, to each group company.

IV. Consolidated Subsidiaries and Affiliates

(As of June 30, 2014)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sales of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
			Chiyoda Kaihatsu Co., Ltd.	100.0%	Contracting, wholesale and retail and insurance agency business
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Supervision and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of antibody technology and accelerating research collaborations (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of new candidate substances under contract (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generation of new candidate substances under contract (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
			ProStrakan Group plc	100.0%	Supervision and management of subsidiaries (UK)
			Strakan International S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
		Europe	Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
			ProStrakan AB	100.0%	Sales of pharmaceuticals (Sweden)
	Asia		Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)
Kyowa Hakko Kirin Korea Co., Ltd.		100.0%	Sales of pharmaceuticals (Korea)		
Kyowa Hakko Kirin (Taiwan) Co., Ltd.		100.0%	Sales of pharmaceuticals (Taiwan)		
Kyowa Hakko Kirin (Hong Kong) Co., Ltd.		100.0%	Sales of pharmaceuticals (Hong Kong)		
Kyowa Hakko Kirin (Singapore) Pte. Ltd.		100.0%	Research and sale of pharmaceuticals (Singapore)		
Affiliate accounted for by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar pharmaceuticals	
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and healthcare products
			DAIICHI FINE CHEMICAL CO., LTD.	100.0%	Manufacture and sales of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BIOKYOWA INC.	100.0%	Manufacture and sales of amino acids (US)
			KYOWA HAKKO U.S.A., INC.	100.0%	Sales of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Supervision and management of subsidiaries (US)
		Europe	KYOWA HAKKO Europe GmbH	100.0%	Sales of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sales of fine chemicals including amino acids (Italy)
		Asia	SHANGHAI KYOWA AMINO ACID CO., LTD.	100.0%	Manufacture and sales of amino acids (China)
			THAI KYOWA BIOTECHNOLOGIES CO., LTD.	100.0%	Manufacture and sales of amino acids (Thailand)
			KYOWA HAKKO (H.K.) CO., LTD.	100.0%	Sales of fine chemicals including amino acids (Hong Kong)
			KYOWA HAKKO BIO SINGAPORE PTE. LTD.	100.0%	Sales of fine chemicals including amino acids (Singapore)

Changes in scope of consolidation resulting in changes in subsidiaries (January 1, 2014 - June 30, 2014)

New: None

Exclusions: None

Japan Synthetic Alcohol Co., Ltd. has been excluded from the scope of affiliates accounted for by the equity method following the disposal of all shares in the company on June 4, 2014.

V. Kyowa Hakko Kirin Sales of main products

Accumulative

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY2014 Forecast		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Kyowa Hakko Kirin total	56.4	106.4	157.0	210.9	52.1	92%	97.0	(9.4)	91%	-	-	-	-	203.0	96%
Indication / Product name															
<i>ESA formulation</i> Nesp	10.6	25.0	39.7	56.0	12.1	114%	25.9	0.8	104%	-	-	-	-	54.9	98%
<i>ESA formulation</i> Espo	0.7	1.5	2.3	3.2	0.6	86%	1.2	(0.3)	80%	-	-	-	-	2.5	79%
Nesp/Espo	11.3	26.5	42.1	59.2	12.8	112%	27.1	0.5	102%	-	-	-	-	57.5	97%
<i>Secondary hyperparathyroidism</i> Regpara	3.0	6.9	10.6	15.1	4.5	148%	7.6	0.7	111%	-	-	-	-	16.0	106%
<i>Secondary hyperparathyroidism</i> Rocaltrol	0.7	1.8	2.8	4.1	1.1	143%	2.1	0.3	118%	-	-	-	-	4.4	108%
<i>Type-2 diabetes</i> Onglyza	-	-	1.1	1.1	0.0	-	0.1	0.1	-	-	-	-	-	1.7	155%
<i>Cardiovascular</i> Coniel	3.5	7.6	11.3	15.5	3.2	91%	6.2	(1.3)	82%	-	-	-	-	12.3	80%
<i>Cardiovascular (Hypertension)</i> Coversyl	0.7	1.6	2.5	3.4	0.7	95%	1.4	(0.2)	88%	-	-	-	-	3.0	86%
<i>G-CSF</i> Gran	2.5	5.8	9.0	12.4	2.0	81%	4.4	(1.4)	76%	-	-	-	-	8.5	69%
<i>Transdermal persistent pain</i> Fentos	1.0	2.3	3.7	5.3	1.1	114%	2.6	0.2	112%	-	-	-	-	6.2	116%
<i>Anticancer</i> Poteligeo	0.2	0.5	0.8	1.1	0.2	97%	0.6	0.1	129%	-	-	-	-	1.4	121%
<i>Anticancer</i> 5-FU	0.6	1.3	2.0	2.7	0.5	93%	1.1	(0.1)	89%	-	-	-	-	2.4	89%
<i>Anticancer</i> Navelbine	0.2	0.5	0.8	1.1	0.2	83%	0.4	(0.1)	79%	-	-	-	-	0.8	78%
<i>Chronic idiopathic thrombocytopenic purpura</i> Romiplate	0.4	1.1	1.7	2.5	0.5	122%	1.2	0.1	110%	-	-	-	-	2.5	101%
<i>Antiallergenic</i> Allelock	10.7	15.9	20.9	27.6	8.4	78%	13.4	(2.5)	84%	-	-	-	-	23.5	85%
<i>Antiallergic eyedrops</i> Patanol	9.4	10.1	11.4	13.4	7.1	75%	8.1	(1.9)	81%	-	-	-	-	11.7	88%
<i>Inflammatory bowel disease</i> Asacol	1.0	2.4	3.8	5.4	1.5	140%	2.7	0.2	112%	-	-	-	-	5.9	108%
<i>Parkinson's disease</i> Nouria	-	0.0	0.2	0.5	0.2	-	0.8	0.7	-	-	-	-	-	3.7	706%
<i>Antiepileptic</i> Depakene	2.3	5.0	7.7	10.5	2.3	100%	4.6	(0.3)	92%	-	-	-	-	9.6	92%
<i>Gastrointestinal</i> Nauzelin	1.0	2.1	3.1	4.5	1.0	99%	1.9	(0.2)	91%	-	-	-	-	4.1	91%
Exports and Technology Out-Licensing															
Exports	3.2	5.4	8.1	10.4	3.4	107%	6.7	1.3	124%	-	-	-	-	10.9	106%
Technology Out-Licensing	4.8	9.7	13.8	15.3	2.0	42%	4.1	(5.5)	43%	-	-	-	-	14.1	92%

V. Kyowa Hakko Kirin Sales of main products

Quarterly

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	%	Apr - Jun	Change amount	%	Jul - Sep	%	Oct - Dec	%
Kyowa Hakko Kirin total	56.4	50.0	50.5	53.8	52.1	92%	44.8	(5.1)	90%	-	-	-	-
Indication / Product name													
ESA formulation Nesp	10.6	14.3	14.7	16.3	12.1	114%	13.7	(0.6)	96%	-	-	-	-
ESA formulation Espo	0.7	0.8	0.8	0.8	0.6	86%	0.6	(0.2)	75%	-	-	-	-
Nesp/Espo	11.3	15.2	15.5	17.1	12.8	112%	14.3	(0.8)	94%	-	-	-	-
Secondary hyperparathyroidism Regpara	3.0	3.8	3.7	4.4	4.5	148%	3.0	(0.7)	81%	-	-	-	-
Secondary hyperparathyroidism Rocaltrol	0.7	1.0	1.0	1.2	1.1	143%	1.0	(0.0)	99%	-	-	-	-
Type-2 diabetes Onglyza	-	-	1.1	0.0	0.0	-	0.1	0.1	-	-	-	-	-
Cardiovascular Coniel	3.5	4.0	3.7	4.1	3.2	91%	2.9	(1.0)	73%	-	-	-	-
Cardiovascular (Hypertension) Coversyl	0.7	0.9	0.8	0.9	0.7	95%	0.7	(0.1)	82%	-	-	-	-
G-CSF Gran	2.5	3.2	3.1	3.4	2.0	81%	2.3	(0.9)	72%	-	-	-	-
Transdermal persistent pain Fentos	1.0	1.3	1.3	1.6	1.1	114%	1.4	0.1	110%	-	-	-	-
Anticancer Poteligeo	0.2	0.2	0.3	0.3	0.2	97%	0.4	0.1	160%	-	-	-	-
Anticancer 5-FU	0.6	0.7	0.6	0.7	0.5	93%	0.6	(0.1)	86%	-	-	-	-
Anticancer Navelbine	0.2	0.2	0.2	0.2	0.2	83%	0.2	(0.0)	76%	-	-	-	-
Chronic idiopathic thrombocytopenic purpura Romiplate	0.4	0.6	0.6	0.7	0.5	122%	0.6	0.0	101%	-	-	-	-
Antiallergenic Allelock	10.7	5.2	4.9	6.7	8.4	78%	4.9	(0.2)	95%	-	-	-	-
Antiallergic eyedrops Patanol	9.4	0.6	1.3	1.9	7.1	75%	1.0	0.4	162%	-	-	-	-
Inflammatory bowel disease Asacol	1.0	1.3	1.4	1.6	1.5	140%	1.2	(0.1)	89%	-	-	-	-
Parkinson's disease Nouriaist	-	0.0	0.1	0.2	0.2	-	0.5	0.4	693%	-	-	-	-
Antiepileptic Depakene	2.3	2.7	2.6	2.8	2.3	100%	2.3	(0.3)	86%	-	-	-	-
Gastrointestinal Nauzelin	1.0	1.1	0.9	1.4	1.0	99%	0.9	(0.1)	82%	-	-	-	-
Exports and Technology Out-Licensing													
Exports	3.2	2.2	2.6	2.3	3.4	107%	3.3	1.0	147%	-	-	-	-
Technology Out-Licensing	4.8	4.8	4.0	1.5	2.0	42%	2.0	(2.7)	43%	-	-	-	-

VI. Segment information and main subsidiaries operating profit or loss

1. Pharmaceuticals segment

(1) Pharmaceuticals segment consolidated total

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	67.4	129.9	192.7	261.0	63.1	94%	119.5	(10.4)	92%	-	-	-	-	252.0	97%
Japan sales	55.2	105.7	155.8	209.3	49.6	90%	92.3	(13.4)	87%	-	-	-	-	198.5	95%
Overseas sales	12.1	24.2	36.9	51.6	13.5	112%	27.2	3.0	112%	-	-	-	-	53.5	104%
America	3.3	7.0	10.3	15.8	3.4	103%	7.2	0.2	104%	-	-	-	-	13.5	85%
Europe	5.8	10.9	17.1	23.0	6.8	118%	13.2	2.3	121%	-	-	-	-	26.2	114%
Asia and others	2.9	6.2	9.4	12.7	3.1	107%	6.6	0.4	107%	-	-	-	-	13.8	108%
Operating income	13.0	24.1	36.9	46.1	9.4	72%	14.1	(9.9)	59%	-	-	-	-	37.0	80%

(2) ProStrakan (GBP)

Millions of GBP, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	35.7	74.2	113.8	155.4	38.4	107%	78.0	3.8	105%	-	-	-	-	163.0	105%
Cancer pain															
Abstral	10.5	22.1	34.3	47.1	12.1	115%	25.7	3.6	116%	-	-	-	-	53.5	114%
Chemotherapy-induced nausea and vomiting drug															
Sancuso	3.0	6.2	9.3	13.8	2.7	90%	6.3	0.0	101%	-	-	-	-	16.6	121%
Replacement therapy with testosterone for male hypogonadism															
Tostran	1.8	4.9	8.7	12.4	2.7	146%	5.9	1.0	121%	-	-	-	-	15.3	123%
Relief of pain associated with chronic anal fissures															
Rectogesic	2.9	6.3	9.2	12.7	2.7	93%	5.6	(0.6)	90%	-	-	-	-	12.5	98%
Osteoporosis drug															
Adcal-D3	6.7	13.5	20.6	28.4	7.1	106%	13.9	0.3	103%	-	-	-	-	28.1	99%
Others	7.0	14.0	20.8	26.6	7.9	113%	15.3	1.2	109%	-	-	-	-	31.4	118%
Product net sales (subtotal)	32.2	67.2	103.2	141.2	35.4	110%	72.9	5.7	108%	-	-	-	-	157.6	112%
Technology Out-Licensing and others	3.4	6.9	10.6	14.1	2.9	84%	5.0	(1.8)	73%	-	-	-	-	5.3	38%
Gross profit	27.4	57.0	87.6	116.5	28.8	105%	58.7	1.6	103%	-	-	-	-	118.5	102%
Selling, general and administrative expenses *1	19.3	39.7	56.8	75.0	17.8	92%	35.2	(4.5)	89%	-	-	-	-	72.9	97%
EBIDTA *2	8.0	17.2	30.8	41.5	10.9	136%	23.5	6.2	136%	-	-	-	-	45.6	110%
Amortization of goodwill and sales rights	9.9	19.9	29.8	39.9	9.9	100%	19.9	(0.0)	100%	-	-	-	-	40.6	102%
Operating income	(1.8)	(2.6)	0.9	1.5	1.0	-	3.5	6.2	-	-	-	-	-	5.0	322%

*1 Amortization of goodwill and sales rights is not included in Selling, general and administrative expenses.

Amortization of goodwill and sales rights= Depreciation + Goodwill amortization.

*2 EBITDA=Operating income + depreciation + goodwill amortization.

*3 Geographical breakdown of sales for Jan - Jun 2014 is as follows:

UK	Europe (excluding UK)	USA	Other
30.0%	47.6%	21.0%	1.4%

(3) Kyowa Medex Co., Ltd.

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	2.5	5.4	8.4	11.7	2.6	105%	5.7	0.2	104%	-	-	-	-	12.0	102%
Japan sales	2.0	4.5	6.9	9.6	2.1	105%	4.6	0.1	103%	-	-	-	-	9.9	103%
Biochemical Diagnostic Reagent	0.8	1.8	2.8	4.0	0.8	103%	1.9	0.0	101%	-	-	-	-	4.1	102%
Immunological Diagnostic Reagent	1.0	2.2	3.4	4.7	1.0	104%	2.3	0.0	104%	-	-	-	-	4.8	103%
Other	0.2	0.3	0.6	0.8	0.2	110%	0.4	0.0	106%	-	-	-	-	0.9	108%
Exports	0.4	0.9	1.5	2.1	0.5	109%	1.0	0.1	114%	-	-	-	-	2.1	98%
Operating income	0.0	0.2	0.4	0.8	0.0	108%	0.3	0.1	151%	-	-	-	-	1.0	122%

VI. Segment information and main subsidiaries operating profit or loss

2. Bio-Chemicals segment

(1) Bio-Chemicals segment consolidated total

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	19.9	41.2	61.5	82.9	23.5	118%	44.0	2.8	107%	-	-	-	-	88.0	106%
Japan sales	11.5	23.4	35.3	48.0	12.9	112%	25.1	1.6	107%	-	-	-	-	49.4	103%
Overseas sales	8.4	17.7	26.2	34.8	10.6	127%	18.8	1.1	107%	-	-	-	-	38.6	111%
America	1.8	4.1	5.9	8.0	2.0	109%	4.1	(0.0)	100%	-	-	-	-	8.9	110%
Europe	3.6	7.5	11.0	14.1	4.1	115%	8.0	0.5	107%	-	-	-	-	16.2	114%
Asia and others	2.9	5.9	9.2	12.6	4.4	152%	6.6	0.6	111%	-	-	-	-	13.5	107%
Operating income	1.4	3.1	4.5	5.6	3.0	206%	4.2	1.1	136%	-	-	-	-	8.0	141%

(2) Kyowa Hakko Bio Co., Ltd.

Billions of yen, rounded down




	FY 2013 results				FY 2014 results								FY 2014 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	13.8	27.8	42.2	57.5	17.3	125%	31.5	3.6	113%	-	-	-	-	60.7	105%
Japan sales	8.8	17.8	26.8	36.1	9.9	112%	19.1	1.2	107%	-	-	-	-	37.4	104%
Pharmaceutical and industrial materials	3.8	7.5	11.3	15.3	4.2	113%	8.1	0.6	108%	-	-	-	-	14.8	97%
Healthcare	2.4	5.3	8.0	11.0	2.6	108%	5.4	0.1	102%	-	-	-	-	11.8	108%
Other	2.5	5.0	7.3	9.7	2.9	115%	5.5	0.4	110%	-	-	-	-	10.6	110%
Exports	4.9	10.0	15.4	21.4	7.4	149%	12.3	2.3	124%	-	-	-	-	23.2	109%
Operating income	1.2	2.2	3.4	4.6	2.7	218%	3.6	1.4	164%	-	-	-	-	5.6	121%

(3) DAIICHI FINE CHEMICAL CO., LTD.

Billions of yen, rounded down







	FY 2013 results				FY 2014 results								FY 2014 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	%	Jan - Jun	Change amount	%	Jan - Sep	%	Jan - Dec	%	Jan - Dec	%
Net sales	2.9	5.8	8.4	12.1	3.5	121%	6.9	1.1	120%	-	-	-	-	13.3	110%
Operating income	(0.0)	(0.2)	(0.5)	(0.9)	(0.0)	-	(0.0)	0.1	-	-	-	-	-	0.3	-

VII. R&D Pipeline















 antibody  protein  small molecule


Filed · Approved

As of Jul 23rd, 2014

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in CN Filed in PH	Licensed from NPS	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients)	Filed in JP		In-House
Oncology		Granisetron Patch	5-HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	NDA in preparation in MY	Licensed from Solasia Pharma (ProStrakan)	Launched by ProStrakan as Sancuso®
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Filed in JP	Kirin-Amgen	
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndrome related Anemia	Filed in JP	Kirin-Amgen	
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Filed in HK, SG, MY TH and TW	Kirin-Amgen	




Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase III in CN	Kirin-Amgen	
		© RTA402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Reata	A new Phase II study in CKD patients with type 2 diabetes will be conducted in JP.
		© KHK7580 Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase I / II in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		© ARQ197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase III in JP	ArQule	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Peripheral T-cell Lymphoma	Phase II in EU	In-House	POTELLIGENT®
				Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others		
				Cutaneous T-cell Lymphoma	Phase III in US, EU and JP		
	AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase II in KR	Kirin-Amgen		
Immunology/Allergy		© KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase III in JP Phase III in KR	In-House	Jointly Developed with AstraZeneca/Medimmune in Japan and South Korea POTELLIGENT®
		© ASKP1240 Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in JP Phase II in US	In-House	Jointly Developed with Astellas KM mouse
		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Ulcerative Colitis Crohn's Disease	Phase III in JP Phase II in JP	Licensed from Zeria Pharma	Jointly Developed with Zeria Pharma The Phase III study is conducted to seek a new dose regimen
		© KHK4827 Brodalumab Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase III in JP	Kirin-Amgen	
		© KHK4577 Oral	Anti-inflammatory Agent	Atopic Dermatitis	Phase II in JP	In-House	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Phase III in US, EU and others	In-House	
Other		© KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase III in JP Phase I in EU	In-House	
		© KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets (XLH) in pediatric patients	Phase II in US/EU	In-House	Jointly Developed with Ultragenyx KM mouse

 Updated since Apr 17th, 2014 (Area, Stage, Filed, Approved, etc.)









© New Molecular Entity


VII. R&D Pipeline

 antibody  protein  small molecule

Phase I

As of Jul 23rd, 2014





Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		◎B1W-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / II a in KR	In-House	POTELLIGENT®
		◎KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in JP	In-House	Being Developed overseas by AVEO as AV-951
		◎KHK2804/ CEP-37250 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in US	Licensed from Teva	Jointly Developed with Teva POTELLIGENT®
		◎KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in SG	In-House	POTELLIGENT® KM mouse
Immunology/ Allergy		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Asthma	Phase I in JP	In-House	POTELLIGENT®
		◎KHK4083 Injection	Immunomodulator Antibody	Autoimmune diseases	Phase I in CA	In-House	POTELLIGENT® KM mouse
Central Nervous System		◎KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU (Not yet recruiting subjects)	Licensed from Immunus Pharma	The application has been accepted by the regulatory authority
Other		◎KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH) in adult patients	Phase I / II in US and CA	In-House	Jointly Developed with Ultragenyx KM mouse

 Updated since Apr 17th, 2014 (Area, Stage, Filed, Approved etc.)




◎ New Molecular Entity

Updated since Apr 17th, 2014 (Area, Stage, Filed, Approved etc.)


Filed · Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in CN	Licensed from NPS	
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients)	Filed in JP	In-House	POTELLIGENT®
		Granisetron Patch	5-HT3 Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	NDA in preparation in MY	Licensed from Solasia Pharma (ProStrakan)	Launched by ProStrakan as Sancuso®
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Filed in HK, SG, MY TH and TW	Kirin-Amgen	



Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase II in KR	Kirin-Amgen	
Immunology/ Allergy		◎KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase III in KR	In-House	Jointly Developed with AstraZeneca/MedImmune in JP and KR POTELLIGENT®
Other		◎KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets (XLH) in pediatric patients	Phase II in US/EU	In-House	Jointly Developed with Ultragenyx KM mouse

Phase I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Central Nervous System		◎KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU (Not yet recruiting subjects)	Licensed from Immunus Pharma	The application has been accepted by the regulatory authority

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		◎ARQ197 Tivantinib Oral	c-Met Inhibitor	Lung Cancer (EGF-receptor mutated)	Phase II in JP	ArQule	
				Gastric Cancer	Phase II in JP and KR		
		◎KW-2478 Injection	HSP90 Inhibitor	Multiple Myeloma	Phase I / II in UK, US and PH	In-House	

<Appendix> Biosimilar Pipeline (Fujifilm Kyowa Kirin Biologics)**Phase I**

As of Jul 23rd, 2014

Code Name	Generic Name	Stage	Remarks
FKB327	Adalimumab (fully human anti-TNF- α monoclonal antibody)	Phase I in UK	